Canada's AmorChem launch­es $44.2M life sci­ence fund; Neon adds $36M, Mer­ck part­ner­ship in neoanti­gen dri­ve; CRISPR Ther­a­peu­tics files a CTA

→ Cana­di­an VC firm AmorChem Group has raised $44.2 mil­lion for its sec­ond life sci­ence fund. Backed by LPs in­clud­ing the Québec gov­ern­ment, Mon­tre­al’s Fonds de sol­i­dar­ité FTQ, and Mer­ck, the new fund is meant to fu­el seed-stage projects com­ing out of Québec-based uni­ver­si­ties and re­search cen­ters. AmorChem launched its first fund back in 2011, and has $86 mil­lion as­sets un­der man­age­ment. The group said two of its projects have been in­volved in suc­cess­ful trans­ac­tions with phar­ma, in­clud­ing the sale of a cys­tic fi­bro­sis as­set from port­fo­lio com­pa­ny Traf­fick Ther­a­peu­tics to Ver­tex Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER